We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The approval is for children aged 6 months to 11 years ...
“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive Officer of ...
Moderna announced on Wednesday it has completed its submission to the US Food and Drug Administration for full approval of its COVID-19 vaccine for people age 18 and older, and Pfizer and BioNTech ...
WASHINGTON -- Moderna is applying for full government approval for its COVID-19 vaccine. The company said it is submitting trial data to the Food and Drug Administration on a rolling basis over the ...
(NewsNation) — Moderna reports it has received full approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Spikevax, in children six months through 11 years of age, who are at ...
Moderna (MRNA) announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP ...
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback